CA3158336A1 - Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide - Google Patents

Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide

Info

Publication number
CA3158336A1
CA3158336A1 CA3158336A CA3158336A CA3158336A1 CA 3158336 A1 CA3158336 A1 CA 3158336A1 CA 3158336 A CA3158336 A CA 3158336A CA 3158336 A CA3158336 A CA 3158336A CA 3158336 A1 CA3158336 A1 CA 3158336A1
Authority
CA
Canada
Prior art keywords
cells
peptide
polypeptide
amino acid
cell fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3158336A
Other languages
English (en)
French (fr)
Inventor
Michiko Koga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3158336A1 publication Critical patent/CA3158336A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3158336A 2019-09-20 2020-09-18 Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide Pending CA3158336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019171919 2019-09-20
JP2019-171919 2019-09-20
PCT/JP2020/035491 WO2021054448A1 (ja) 2019-09-20 2020-09-18 ペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物

Publications (1)

Publication Number Publication Date
CA3158336A1 true CA3158336A1 (en) 2021-03-25

Family

ID=74883555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3158336A Pending CA3158336A1 (en) 2019-09-20 2020-09-18 Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide

Country Status (8)

Country Link
US (1) US20230034205A1 (https=)
EP (1) EP4032589A4 (https=)
JP (2) JP7329056B2 (https=)
KR (1) KR20220066309A (https=)
CN (1) CN114423778B (https=)
AU (1) AU2020349967A1 (https=)
CA (1) CA3158336A1 (https=)
WO (1) WO2021054448A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022202785A1 (ja) * 2021-03-22 2022-09-29 美智子 甲賀 ポリペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5768790A (en) * 1980-10-15 1982-04-27 Hidetoshi Tsuchida Cell fusion agent
DE3321226C2 (de) * 1983-06-11 1985-05-09 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren zur Fusion von Zellen
JP3099049B2 (ja) * 1992-07-29 2000-10-16 農林水産省果樹試験場長 電気的細胞融合及び電気的核酸導入のための大量処理用電極
EP1454988A1 (en) * 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
US20080176923A1 (en) * 2003-12-18 2008-07-24 Salama Zoser B Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors
EP1831373A2 (en) * 2004-12-22 2007-09-12 Novozymes A/S Recombinant production of serum albumin
EP2508606B1 (en) * 2006-10-24 2017-09-13 Momotaro-Gene Inc. Partial fragment of REIC/Dkk-3 gene and therapeutic agent for cancer containing the same
EP2323679A4 (en) * 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
CN107201344A (zh) * 2017-06-13 2017-09-26 成都源泉生物科技有限公司 一种动物细胞融合基础培养基
CN108315319A (zh) * 2018-02-05 2018-07-24 翁炳焕 一种cd138单抗靶向捕获的细胞融合方法
CN108707600A (zh) * 2018-05-31 2018-10-26 东北农业大学 一种猪鼠细胞单细胞融合方法

Also Published As

Publication number Publication date
EP4032589A4 (en) 2023-12-20
JPWO2021054448A1 (https=) 2021-03-25
JP2023133582A (ja) 2023-09-22
JP7329056B2 (ja) 2023-08-17
EP4032589A1 (en) 2022-07-27
KR20220066309A (ko) 2022-05-24
US20230034205A1 (en) 2023-02-02
CN114423778B (zh) 2024-05-24
WO2021054448A1 (ja) 2021-03-25
CN114423778A (zh) 2022-04-29
AU2020349967A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
ES2287948T3 (es) Ligando apo-2.
JP7042854B2 (ja) 抗ｎｍｅ抗体
US8834872B2 (en) Uses of antibodies
EA022308B1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
EA009026B1 (ru) Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях
EA007471B1 (ru) Растворимый рецептор br43x2 и способы его применения
EA007275B1 (ru) Слитые белки taci-иммуноглобулина
BR112014016076B1 (pt) Peptídeo, vetor, construção de peptídeo quimérico e composição farmacêutica
EA015706B1 (ru) Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
KR20190085935A (ko) 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
US20080187542A1 (en) Compositions and methods for the treatment of immunologic disorders
US20230034205A1 (en) Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide
US20250129122A1 (en) Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide
HU228978B1 (en) Use of long pentraxin ptx3 for treating female infertility
CN116262785A (zh) 抗抑制素抗体及其应用
HK40074633A (en) Peptide, and cell fusion agent and pharmaceutical composition for cancer therapy containing said peptide
HK40074633B (zh) 肽及包含该肽的细胞融合剂以及用於癌症治疗的药物组合物
JP7195621B2 (ja) 細胞殺傷剤
JP7202662B2 (ja) ワクチン組成物
CN106674353A (zh) 一种新的天花粉融合蛋白及其应用
US9526717B2 (en) Composition for treating immune diseases containing daurinol compound as active ingredient
KR20130060846A (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
CN103539840B (zh) 表皮生长因子受体模拟表位肽及其应用
US20150132285A1 (en) Proteinase-engineered Cancer Vaccine Induces Immune Responses to Prevent Cancer and to Systemically Kill Cancer Cells
CN121673368A (zh) 细胞死亡诱导肽、含有其的功能偶合多肽或融合蛋白及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231005

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241108

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250227

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250619

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250619